TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities

Benzinga Logo Benzinga By Vandana Singh
Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities

Bristol Myers Squibb is continuing patient enrollment in its ADEPT-2 Phase 3 study for Cobenfy after identifying clinical trial irregularities. The Data Monitoring Committee recommended continuing the study, and additional trial results are now expected by the end of 2026.

Insights
CMA   neutral

Being acquired by Fifth Third Bancorp, shareholders receiving 1.8663 shares per existing share


BMY   neutral

The company is proactively addressing clinical trial irregularities and continuing research with FDA and DMC support, indicating responsible management despite potential delays